Abstract 125: Protein kinase C loss-of-function mutations in cancer reveal role as tumor suppressor

Abstract

Abstract Protein kinase C (PKC) remains an elusive chemotherapeutic target despite decades of research. To determine whether PKC isozymes function as oncogenes or tumor suppressors, we analyzed 8% of PKC mutations identified in human cancers. Surprisingly, the majority were loss-of-function and none were activating. Loss-of-function mutations were found in all PKC subgroups and acted by impeding 2nd messenger binding or preventing processing phosphorylations. Bioinformatic analysis revealed that PKC mutations might cooperate with co-occurring mutations in cancer drivers. Correction of a patient-identified, loss-of-function PKCβ mutation by CRISPR-mediated genome editing, in a colon cancer cell line, suppressed anchorage-independent growth and reduced tumor growth in xenograft models. Hemizygous deletion provided an anchorage-independent growth advantage, revealing PKC is haploinsufficient for tumor suppression. Several mutations were dominant-negative, suppressing global PKC signaling output. These data establish that PKC isozymes generally function as tumor suppressors, indicating that therapeutic strategies should focus on restoring PKC activity, not inhibiting it. Citation Format: Corina E. Antal, Andrew M. Hudson, Emily Kang, Ciro Zanca, Christopher Wirth, Natalie L. Stephenson, Eleanor W. Trotter, Lisa L. Gallegos, Crispin Miller, Frank Furnari, Tony Hunter, John Brognard, Alexandra C. Newton. Protein kinase C loss-of-function mutations in cancer reveal role as tumor suppressor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 125. doi:10.1158/1538-7445.AM2015-125